8-K filing — PDS Biotechnology Corp (PDSB)
Filed: 2026-11-10 AccNo: 0001140361-26-042898 Size: 171 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
PDS Biotechnology Announces Exercise of Warrants by NantWorks for $3.9 Million
PDS Biotechnology Corporation announced that NantWorks has exercised warrants to purchase over 17.6 million shares of common stock, generating approximately $3.9 million in gross proceeds.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
PDS Biotech Announces ~$3.9M Gross Proceeds From NantWorks Exercise Of Warrants For 17,699,115 Shares At $0.22/Share
B. Riley Securities Raises Price Target on PDS Biotechnology to $4
B. Riley Securities has maintained its 'Buy' rating on PDS Biotechnology while increasing the price target from $3 to $4.
PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors
PDS Biotechnology Corporation has expanded its Board of Directors with the appointment of three new members with extensive pharmaceutical industry experience.
PDS Biotechnology shares are trading higher after the company announced the publication of Phase 2 trial results for PDS0101 in combination with pembrolizumab in JAMA Oncology.
Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care
The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.